Loading...
XSHE
000931
Market cap504mUSD
Oct 09, Last price  
4.59CNY
1D
2.46%
1Q
8.00%
Jan 2017
-45.81%
Name

Beijing Centergate Technologies Holding Co Ltd

Chart & performance

D1W1MN
XSHE:000931 chart
P/E
72.19
P/S
1.43
EPS
0.06
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
6.23%
Revenues
2.42b
-4.38%
488,813,8082,232,309,1812,056,061,3122,329,444,6762,599,059,5183,310,476,8703,270,537,0223,605,177,8513,034,196,9251,078,026,3191,478,567,3571,740,701,0551,773,506,8042,135,149,0421,789,615,9001,955,834,3892,060,280,7072,276,603,3452,532,142,1972,421,200,324
Net income
48m
-10.65%
4,191,42489,018,19960,527,67749,919,15810,461,78041,637,63829,888,445013,750,904152,389,92927,358,13814,261,57993,140,19495,218,08755,389,0080048,574,06353,592,19047,885,454
CFO
39m
-69.21%
0720,544,525196,034,807186,229,097183,584,205243,578,9600497,422,724000158,797,288205,222,888164,165,782200,200,020263,413,088183,742,331218,298,525127,601,58839,283,429
Dividend
Jun 12, 20260.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Centergate Technologies (holding) Co., Ltd. is a multifaceted corporation with a presence in both domestic Chinese and international markets. Its principal activities include the manufacturing and distribution of pharmaceuticals, undertaking construction projects, developing real estate, and providing property management services. The company's pharmaceutical division offers a diverse range of medicinal products, such as huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, and naloxone hydrochloride, along with various tablets and capsules like five plus biochemical and aramol quramado. In addition to traditional medicines, Beijing Centergate Technologies produces specialized oral and mucous membrane repair and health products, encompassing toothpaste, mouthwash, sprays, and dental equipment. These items are designed to address issues like ulcers, burns, mechanical damage, and support post-operative healing. Furthermore, the company supplies nutritional products and food-grade raw materials, including fruit enzymes, imported fungella enzymes, beneficial probiotics, and soda. Beyond its operational segments, the firm also allocates investments to high-tech sectors such as software, communications and electronic engineering, biomedicine, and other areas within the life sciences. Established in Beijing, China, in 1999, the company remains headquartered in its founding city.

Key people

Zhongmin Xu
Chairman of the Board · since 2019
Xuewu Song
Chief Financial Officer, Vice President · since 2022
Dehui Che
Vice President · since 2022
Xiujun Fan
Vice President · since 2022
Zhiyu Huang
Vice President, Company Secretary · since 2022
Bin Li
Vice President · since 2016
Xihong Wang
Vice President · since 2022
Ping Chen
Director · since 2012
Zhanjun Hou
President, Director · since 2019
Xiuhong Huang
Director · since 2009
Ye Zhang
Director · since 2012
Director · since 2012
Ke Bi
Independent Director · since 2022
Independent Director · since 2022
Qin Xia
Independent Director · since 2025
IPO date
Jul 12, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT